2-acetylthiomethyl-5-phenylpentanoic acid | 116112-43-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-acetylthiomethyl-5-phenylpentanoic acid
• 英文别名: 2-acetylthiomethyl-5-phenylvaleric acid；2-(acetylsulfanylmethyl)-5-phenylpentanoic acid
• CAS: 116112-43-7
• 化学式: C₁₄H₁₈O₃S
• 分子量: 266.361
• InChiKey: OLEKVZMXQWHUMS-UHFFFAOYSA-N

物化性质

• 沸点：
  438.1±45.0 °C(Predicted)
• 密度：
  1.171±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  18
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  79.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-acetylthiomethyl-5-phenylpentanoic acid 在 sodium hydroxide 、 氯化亚砜 作用下， 以 四氢呋喃 、 氯仿 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 Sodium; 2-(2-acetylsulfanylmethyl-5-phenyl-pentanoylamino)-ethanesulfonate
  参考文献：
  名称：

  一类新的含有C端磺基的脑啡肽酶抑制剂。

  摘要：

  合成了一系列新的磺酸，并测试了它们对脑啡肽酶的抑制活性。其中，最有效的是N-（2-苄基-3-巯基丙酰基）偏苯甲酸10i，IC50值为0.27 nM。几种其他类似物（10a，b，j，n，o，gg，hh）显示出与C端含脑啡肽酶的C末端抑制剂硫柳芬（IC50 = 2.6 nM）相当或更高的抑制活性。因此，发现含有C端磺基而不是C端羧基的化合物显示出对脑啡肽酶的抑制作用显着高水平。还通过苯基苯醌扭曲试验评价了10b，（S）-10b和（R）-10b的镇痛活性。

  DOI：

  10.1021/jm00081a024
• 作为产物：
  描述：

  2-methylene-5-phenylpentanoic acid 以 硫代乙酸 为溶剂， 以100%的产率得到2-acetylthiomethyl-5-phenylpentanoic acid
  参考文献：
  名称：

  Pyrrolidine and thiazole derivatives with antibacterial and .

  摘要：

  这项发明涉及一种治疗人类或动物细菌感染的方法，包括与β-内酰胺抗生素结合，同时给予式(I)化合物的治疗有效量。

  公开号：

  US06022885A1

文献信息

• N-substituted mercaptopropanamide derivatives
  申请人：Dainippon Pharmaceutical Co., Ltd.

  公开号：US05179125A1

  公开（公告）日：1993-01-12

  Novel N-substituted mercaptopropanamide derivatives of the formula: ##STR1## wherein R.sub.1 is mercapto or a group convertible into mercapto when cleaved within the biobody, W is hydrogen atom, an alkyl or an aralkyl, R.sub.2 is an aryl which may optionally have substituent(s), a heterocyclic group which may optionally have substituent(s), or an alkyl which may optionally have substituent(s), X is a cycloalkylene, a cycloalkylidene, or a phenylene which may optionally have substituent(s) or may optionally be fused with other ring, and R.sub.3 is carboxyl or a group convertible into carboxyl when cleaved within the biobody, or a pharmaceutically acceptable salt thereof, and a solid solution of said N-substituted mercaptopropanamide derivative with an amino acid, which have excellent enkephalinase inhibitory activity and are useful for the treatment of mild to moderate pain, and a pharmaceutical composition containing said compounds as an active ingredient, and processes for preparing these compounds.

  N-取代巯基丙酰胺衍生物的化学式为：##STR1## 其中R.sub.1是巯基或在生物体内裂解时可转化为巯基的基团，W是氢原子、烷基或芳基烷基，R.sub.2是芳基，可选择地具有取代基，是可能可选择地具有取代基的杂环基，或是可能可选择地具有取代基的烷基，X是环烷基、环烷基亚甲基或苯亚甲基，可选择地具有取代基或可选择地与其他环融合，R.sub.3是羧基或在生物体内裂解时可转化为羧基的基团，或其药学上可接受的盐，以及所述N-取代巯基丙酰胺衍生物与氨基酸的固体溶液，具有优异的脑内啡酰肽酶抑制活性，适用于轻至中度疼痛的治疗，以及含有所述化合物作为活性成分的药物组合物，以及制备这些化合物的方法。
• .beta.-thiopropionyl-aminoacid derivatives and their use as
  申请人：SmithKline Beecham p.l.c.

  公开号：US06048852A1

  公开（公告）日：2000-04-11

  A method of treatment of bacterial infections in humans or animals which comprises administering, in combination with a .beta.-lactam antibiotic, a therapeutically effective amount of an amino acid derivative of Formula (I) or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof, ##STR1## wherein: R is hydrogen, a salt forming cation or an in vivo hydrolysable ester-forming group; R.sub.1 is hydrogen, (C.sub.1-6)alkyl optionally substituted by up to three halogen atoms or by a mercapto, (C.sub.1-6)alkoxy, hydroxy, amino, nitro, carboxy, (C.sub.1-6)alkylcarbonyloxy, (C.sub.1-6)alkoxycarbonyl, formyl or (C.sub.1-6)alkylcarbonyl group, (C.sub.3-7)cycloalkyl, (C.sub.3-7)cycloalkyl(C.sub.2-6)alkyl, (C.sub.2-6)alkenyl, (C.sub.2-6)alkynyl, aryl, aryl(C.sub.1-6)alkyl, heterocyclyl or heterocyclyl(C.sub.1-6)alkyl; R.sub.2 is hydrogen, (C.sub.1-6)alkyl or aryl(C.sub.1-6)alkyl; R.sub.3 is hydrogen, (C.sub.1-6)alkyl optionally substituted by up to three halogen atoms, (C.sub.3-7)cycloalkyl, fused aryl(C.sub.3-7)cycloalkyl, (C.sub.3-7)cycloalkyl(C.sub.2-6)alkyl, (C.sub.2-6)alkenyl, (C.sub.2-6)alkynyl, aryl, aryl-(CHR.sub.10).sub.m --X--(CHR.sub.11).sub.n, heterocyclyl or heterocyclyl-(CHR.sub.10).sub.m --X--(CHR.sub.11).sub.n, where m is 0 to 3, n is 1 to 3, each R.sub.10 and R.sub.11 is independently hydrogen or (C.sub.1-4)alkyl and X is O, S(O).sub.x where x is 0-2, or a bond; R.sub.4 is hydrogen, or an in vivo hydrolysable acyl group; and R.sub.5 and R.sub.6 are independently hydrogen and (C.sub.1-6)alkyl or together represent (CH.sub.2).sub.p where p is 2 to 5. Some compounds are claimed per se.

  一种治疗人类或动物细菌感染的方法，包括与β-内酰胺类抗生素联合给药，给予公式(I)的氨基酸衍生物的治疗有效量或其药用可接受的盐、溶剂化合物或体内可水解酯的治疗有效量，其中：R为氢、形成盐的阳离子或体内可水解酯形成基团；R.sub.1为氢、(C.sub.1-6)烷基，可选地被高达三个卤素原子或巯基、(C.sub.1-6)烷氧基、羟基、氨基、硝基、羧基、(C.sub.1-6)烷基羰氧基、(C.sub.1-6)烷氧羰基、甲酰基或(C.sub.1-6)烷基羰基取代，(C.sub.3-7)环烷基，(C.sub.3-7)环烷基(C.sub.2-6)烷基，(C.sub.2-6)烯基，(C.sub.2-6)炔基，芳基，芳基(C.sub.1-6)烷基，杂环烷基或杂环烷基(C.sub.1-6)烷基；R.sub.2为氢，(C.sub.1-6)烷基或芳基(C.sub.1-6)烷基；R.sub.3为氢，(C.sub.1-6)烷基，可选地被高达三个卤素原子取代，(C.sub.3-7)环烷基，融合的芳基(C.sub.3-7)环烷基，(C.sub.3-7)环烷基(C.sub.2-6)烷基，(C.sub.2-6)烯基，(C.sub.2-6)炔基，芳基，芳基-(CHR.sub.10).sub.m --X--(CHR.sub.11).sub.n，杂环烷基或杂环烷基-(CHR.sub.10).sub.m --X--(CHR.sub.11).sub.n，其中m为0至3，n为1至3，每个R.sub.10和R.sub.11独立地为氢或(C.sub.1-4)烷基，X为O，S(O).sub.x，其中x为0-2，或键；R.sub.4为氢，或体内可水解的酰基；R.sub.5和R.sub.6独立地为氢和(C.sub.1-6)烷基，或一起代表(CH.sub.2).sub.p，其中p为2至5。一些化合物本身被要求。
• PYRROLIDINE AND THIAZOLE DERIVATIVES WITH ANTIBACTERIAL AND METALLO-BETA-LACTAMASE INHIBITORY PROPERTIES
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP0850230A1

  公开（公告）日：1998-07-01
• BETA-THIOPROPIONYL-AMINOACID DERIVATIVES AND THEIR USE AS BETA-LACTAMASE INHIBITORS
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP0900197A1

  公开（公告）日：1999-03-10
• US5179125A
  申请人：——

  公开号：US5179125A

  公开（公告）日：1993-01-12